Bifidobacterium lactis XLTG11 Reduces Eczema and Infections in Infants: A Randomized Trial.
Yanhan Yuan, Xiaotong Yin, Jingjing Liu...
https://pubmed.ncbi.nlm.nih.gov/42308545/Actively Recruiting
Led by Min-Tze LIONG · Updated on 2026-04-01
366
Participants Needed
2
Research Sites
N/A
Total Duration
This research aims to study healthy infants and young children under 3 years old who have a higher risk of allergies. It evaluates the effects of daily supplementation with the probiotic Bifidobacterium animalis subsp. lactis XLTG11 compared to a placebo over 180 days. The study focuses on allergic, respiratory, and gastrointestinal symptoms and investigates how the probiotic may influence the gut microbiome and immune system during early development. Participants are randomly assigned to one of two groups one receiving a daily sachet containing the probiotic 1 10 CFU per 2 g dose with maltodextrin, and the other receiving a placebo sachet with maltodextrin only. The intervention lasts for 180 days. Fecal samples are collected before and after treatment to analyze gut bacteria composition, functional pathways, and immune markers such as -defensin 2, LL-37, calprotectin, and secretory IgA. During the study, caregivers will complete clinical questionnaires and maintain daily stool diaries to track allergy symptoms, stool frequency, and consistency. Researchers will measure growth and development using standardized anthropometric scores. Laboratory tests include metagenomic sequencing of fecal samples and immune biomarker analysis. The study aims to understand how the probiotic affects symptom burden, gut health, and immune function over the 180-day period.
CONDITIONS
To Investigate the Effects of Bifidobacterium Animalis Subsp. Lactis XLTG11 on Growth and Development, Incidence of Allergy and Immune Function in Infants
M
Min Tze Liong, Ph.D.
J
Jie Yuan, M.Sc.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Min-Tze LIONG
Lead Sponsor
Shanghai 6th People's Hospital
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 180 days
Participants receive daily probiotic or placebo sachets to evaluate effects on growth, allergy incidence, and immune function.
Baseline visit and follow-up visit at Day 180
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Yanhan Yuan, Xiaotong Yin, Jingjing Liu...
https://pubmed.ncbi.nlm.nih.gov/42308545/Min-Tze LIONG
Lead Sponsor
Shanghai 6th People's Hospital
Collaborating Sponsor